Education Hub

Harm Reduction

Evidence-based strategies for risk reduction, set and setting, and safety guidelines for informed decision-making.

19 articles available

Start Here

Harm Reduction Basics

Risk-reduction strategies, evidence limitations, and crisis resources for informed decision-making.

10 min

Set and Setting

The foundational harm reduction concept that emphasizes mindset and environment.

8 min

Dosing Guide

General reference ranges with potency uncertainty and risk limitations; not personal advice.

10 min

Contraindications & Drug Interactions

Documented and possible risks involving SSRIs, MAOIs, lithium, and heart conditions.

15 min

Crisis & Difficult Experiences

Grounding techniques and support for challenging psychedelic experiences.

12 min

Cannabis & Psychedelics

Evidence-limited information on cannabis and psilocybin timing, interactions, and risks.

10 min

Integration Practices

Post-experience processing — journaling, therapy, and behavior change.

12 min

MDMA Dosing Guide

General MDMA ranges, redosing risks, uncertainty, and limitations; not a body-weight recommendation.

15 min

Ketamine Safety & Clinical Use

Clinical distinctions, escalating risk signs, emergency guidance, and authoritative sources.

15 min

LSD Dosing Guide

General LSD ranges, uncertain potency, tolerance, and testing limitations; not personal advice.

15 min

DMT Dosing Guide

General DMT range education by route with variability and MAOI risks; not personal advice.

16 min

Ibogaine Dosing Guide

Published ibogaine protocol context, cardiac risk, and medical screening; not self-dosing guidance.

16 min

Mescaline & Peyote Dosing Guide

General mescaline ranges, uncertain cactus potency, and conservation context; not a recommendation.

14 min

Cannabis Dosing Guide

General cannabis ranges, delayed onset, variable response, interactions, and legal context.

14 min

Related Journal Articles

Psychedelic Alpha
Law & Ethics

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine produ...

EvanderOct 30, 20261 min
Psychedelics Today
Law & Ethics
Harm Reduction

From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics

Documentary filmmaker Jordan Kronick joins Joe to discuss Peaking: Psychedelics and the Pursuit of Happiness, a new psychedelic documentary that takes cameras into the dosing room across six psychedel...

Psychedelics TodayOct 21, 20261 min
Psychedelics Today
Research & History
Law & Ethics

Weekly Psychedelic Policy Briefing: October 12, 2026

FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling.

Psychedelics TodayOct 12, 20261 min
Psychedelics Today
Law & Ethics
Harm Reduction

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Kenneth Tupper joins Joe Moore for a wide-ranging conversation on harm reduction, drug education, British Columbia’s toxic drug crisis, ayahuasca policy, entheogenic education, and what psychedelic pu...

Psychedelics TodayOct 7, 20261 min
MAPS
Law & Ethics
Harm Reduction

2026 Third Quarter — Legislative Wrap Up

Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use...

Kevin CranfordOct 6, 20267 min

By continuing to use this site, you agree to our Terms and Privacy Policy.

Common questions

What does the Harm Reduction section cover?
It collects educational resources on risk reduction, set and setting, safety guidance, and informed decision-making.
Do harm-reduction practices remove all risk?
No. The page describes risk-reduction information and does not promise that risks can be eliminated.